Get the Stockscreener App
5.1901
2.37%
0.1201
Vyome Holdings Inc stock is traded at $5.1901, with a volume of 10,589.
It is up +2.37% in the last 24 hours and down -28.90% over the past month.
Vyome Holdings Inc is a clinical stage specialty pharmaceutical company working to treat immuno-inflammatory diseases including rare indications of unmet need with next-generation therapeutic solutions.
See More
Previous Close:
$5.07
Open:
$5.09
24h Volume:
10,589
Relative Volume:
0.04
Market Cap:
$27.85M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-1.14%
1M Performance:
-28.90%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$5.0801
$5.3727
1-Week Range:
$5.01
$6.4499
52-Week Range:
$5.01
$12.87
Vyome Holdings Inc Stock (HIND) Company Profile
Name
Vyome Holdings Inc
Sector
Industry
Phone
949-429-6680
Address
1001 CALLE AMANECER, SAN CLEMENTE
Compare HIND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HIND
Vyome Holdings Inc
|
5.3727 | 27.85M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.85 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.67 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.62 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.98 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.25 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vyome Holdings Inc Stock (HIND) Latest News
Head-To-Head Comparison: Vyome (NASDAQ:HIND) vs. Bioventus (NASDAQ:BVS) - Defense World
Head to Head Survey: Vyome (NASDAQ:HIND) versus CapsoVision (NASDAQ:CV) - Defense World
Maxim Group Reaffirms “Buy” Rating for Vyome (NASDAQ:HIND) - Defense World
Vyome Holdings Acquires AI Startup Oculo, Inc. - TipRanks
Vyome Holdings acquires Oculo Health - Medical Buyer
Vyome Holdings Acquires MIT Spinout Oculo Health, Launches AI Psychiatrist Business Unit - Sahyadri Startups
Vyome Holdings Acquires MIT AI Spinout Oculo Health - citybiz
Vyome acquires AI startup Oculo to develop inflammation-focused digital therapeutics By Investing.com - Investing.com South Africa
Vyome acquires AI startup Oculo to develop inflammation-focused digital therapeutics - Investing.com Nigeria
Vyome Holdings acquires MIT AI spinout Oculo Health - MarketScreener
Vyome shares surge after encouraging preclinical data for eye treatment - MSN
BC-Most Active Stocks - upstatetoday.com
Why Is BBAI Stock Falling Today? - Stocktwits
HIND Stock Rallies 70% Pre-Market Today Find Out Why - Menafn
HIND Stock: Growth or Bubble? - StocksToTrade
HIND Stock Rallies 70% Pre-Market Today – Find Out Why - Asianet Newsable
Vyome Holdings (HIND) Skyrockets Over 50% on Breakthrough Uveitis Treatment News - RagingBull
Vyome stock soars after positive preclinical results for eye drug - Investing.com India
Vyome stock soars after positive preclinical results for eye drug By Investing.com - Investing.com Nigeria
Morning Market Movers: SPRC, HIND, SQFT, FGNX See Big Swings - RTTNews
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity - Business Wire
Vertiv’s Stock Surge: Will it Last? - StocksToTrade
Vyome Holdings Appoints Dr. Richard Fahrner as CTO and Dr. Tamara Agajanov, MD, as SVP – Clinical Development - citybiz
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies - PharmiWeb.com
Vyome Holdings strengthens leadership team with industry veterans as it plans pivotal trial studies - MarketScreener
Vyome Holdings Completes Merger with Vyome Therapeutics - MSN
Vyome’s VT-1953 shows significant reduction in cancer wound odor By Investing.com - Investing.com Nigeria
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity - biospace.com
Vyome’s VT-1953 shows significant reduction in cancer wound odor - Investing.com India
Vyome Holdings Inc positive interim data from Phase 2 Study of VT-1953 in malignant fungating wounds - MarketScreener
Vyome Holdings completes merger with Vyome Therapeutics and files financials By Investing.com - Investing.com Canada
Vyome Holdings completes merger with Vyome Therapeutics and files financials - Investing.com
Vyome Holdings, Embryyo Technologies Partner on AI Medtech - Medical Product Outsourcing
Vyome, Embryyo form partnership to pursue AI-enabled medical devices - Medical Economics
US-based Vyome signs MoU with India’s leading medical device innovation studio Embryyo - BioSpectrum India
Vyome And Embryyo Sign MoU To Develop AI-Enabled Medical Devices - Sahyadri Startups
Vyome Holdings, Inc. Signs MoU with Embryyo Technologies - MarketScreener
Vyome, India's Embryyo Sign MOU to Pursue AI Medical Device Market; Shares up Pre-Bell - MarketScreener
Vyome partners with Embryyo to enter AI-enabled medical device market - Investing.com
Vyome Signs MoU with Embryyo, India’s Leading Medical Device Innovation Studio - FinancialContent
Vyome Holdings expands at-the-market offering and appoints new auditor - Investing.com India
Vyome Holdings expands at-the-market offering and appoints new auditor By Investing.com - Investing.com South Africa
Vyome Holdings Amends Equity Distribution Agreement - TipRanks
Vyome Amends Equity Distribution Agreement with ReShape Lifesciences Inc. - AInvest
Vyome Holdings Inc Stock (HIND) Financials Data
There is no financial data for Vyome Holdings Inc (HIND). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.07%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):